These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3202277)

  • 1. Specific immunotherapy.
    Bousquet J; Michel FB
    Allergy; 1988; 43 Suppl 8():16-22. PubMed ID: 3202277
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
    Rossi RE; Monasterolo G
    Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on vaccines for specific immunotherapy.
    Jensen-Jarolim E; Wallmann J; Szalai K; Epstein M; Singh P; Hartl A; Thalhamer J; Pali-Scholl I
    Drugs Today (Barc); 2008 Dec; 44 Suppl B():97-8. PubMed ID: 19221632
    [No Abstract]   [Full Text] [Related]  

  • 4. Adverse effects and fatalities associated with subcutaneous allergen immunotherapy.
    Bukantz SC; Bagg AS; Lockey RF
    Clin Allergy Immunol; 2008; 21():455-68. PubMed ID: 18828523
    [No Abstract]   [Full Text] [Related]  

  • 5. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
    Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
    J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term immunological effects of Japanese cedar pollen-based subcutaneous immunotherapy.
    Inuo C; Ando H; Tanaka K; Nakajima Y; Tsuge I; Urisu A; Kondo Y
    Allergol Int; 2018 Jul; 67(3):408-410. PubMed ID: 29198713
    [No Abstract]   [Full Text] [Related]  

  • 7. Vaccination for birch pollen allergy: comparison of the affinities of specific immunoglobulins E, G1 and G4 measured by surface plasmon resonance.
    Jakobsen CG; Bodtger U; Poulsen LK; Roggen EL
    Clin Exp Allergy; 2005 Feb; 35(2):193-8. PubMed ID: 15725191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy. When indicated and how it works.
    Windom HH
    J Fla Med Assoc; 1996; 83(6):419-22. PubMed ID: 8752371
    [No Abstract]   [Full Text] [Related]  

  • 9. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
    Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
    J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring the epitope recognition profiles of IgE, IgG1, and IgG4 during birch pollen immunotherapy.
    Gepp B; Lengger N; Möbs C; Pfützner W; Radauer C; Bohle B; Breiteneder H
    J Allergy Clin Immunol; 2016 May; 137(5):1600-1603.e1. PubMed ID: 26686470
    [No Abstract]   [Full Text] [Related]  

  • 11. Allergen immunotherapy.
    Mannan S
    Immunotherapy; 2017 Nov; 9(15):1199-1200. PubMed ID: 29130796
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pollen-induced allergy. Programming and monitoring of specific immunotherapy].
    Obtułowicz K
    Folia Med Cracov; 1988; 29(1-2):21-48. PubMed ID: 3255656
    [No Abstract]   [Full Text] [Related]  

  • 13. Next generation immunotherapy for tree pollen allergies.
    Su Y; Romeu-Bonilla E; Heiland T
    Hum Vaccin Immunother; 2017 Oct; 13(10):2402-2415. PubMed ID: 28853984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local reactions from subcutaneous allergen immunotherapy.
    Coop CA
    Immunotherapy; 2013 Dec; 5(12):1339-45. PubMed ID: 24283844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyposensitization (immunotherapy) in allergic diseases: an introduction.
    Fuchs E
    Allergol Immunopathol (Madr); 1981; Suppl 9():167-70. PubMed ID: 7349726
    [No Abstract]   [Full Text] [Related]  

  • 16. Evidence of a common regulation of IgE and IgG-subclass antibodies in humans during immunotherapy.
    Søndergaard I; Poulsen LK; Osterballe O; Weeke B
    Allergy; 1992 Oct; 47(5):467-70. PubMed ID: 1485649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
    Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
    Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy.
    Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
    J Allergy Clin Immunol; 2014 Sep; 134(3):741-744.e5. PubMed ID: 24934275
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative efficacy and safety of subcutaneous versus sublingual immunotherapy.
    Bauer CS; Rank MA
    J Allergy Clin Immunol; 2014 Sep; 134(3):765-765.e2. PubMed ID: 25171871
    [No Abstract]   [Full Text] [Related]  

  • 20. Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Birch Pollen Preparation.
    Buczyłko K; van der Werf JF; Boot D; van Ree R
    Int Arch Allergy Immunol; 2017; 172(3):183-186. PubMed ID: 28380494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.